<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135588</url>
  </required_header>
  <id_info>
    <org_study_id>ERMC 13-29</org_study_id>
    <nct_id>NCT02135588</nct_id>
  </id_info>
  <brief_title>Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of intrapleural dornase alfa&#xD;
      and tPA administered to patients with clinical failure of small-bore chest tube with&#xD;
      persistent pleural effusions or malignancy-related loculated effusion to improve pleural&#xD;
      drainage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic improvement in area of pleural collection</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Loculated or Non-draining Malignant Pleural Effusions</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-pleural deoxyribonuclease 5mg and intra-pleural Alteplase 10mg, every 12 hours over 72 hours (total of 6 treatments)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)</intervention_name>
    <arm_group_label>Active Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical failure of small-bore chest tube with persistent pleural effusion&#xD;
&#xD;
          2. 18 years of age or older&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2.&#xD;
&#xD;
          4. Life expectancy ≥ 6 weeks&#xD;
&#xD;
          5. Absolute neutrophil count &gt; 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.0&#xD;
             g/dL&#xD;
&#xD;
          6. Serum creatinine ≤2.0 times the upper limit of the normal range, total bilirubin ≤ 2.5&#xD;
             mg/dL, AST/ALT ≤ 5 times the upper limit of normal range&#xD;
&#xD;
          7. At least 2 days from administration of chemotherapy&#xD;
&#xD;
          8. At least 7 days from prior major surgery&#xD;
&#xD;
          9. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically&#xD;
             sterile) must be willing to use an acceptable contraceptive method (abstinence, oral&#xD;
             contraceptive or double barrier method) for the duration of the study and for 30 days&#xD;
             following the last dose of study drug, and must have a negative urine or serum&#xD;
             pregnancy test within 2 weeks prior to beginning treatment on this trial.&#xD;
&#xD;
         10. Patient judged to be 'medically stable' by primary investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with intrapleural fibrinolytic agents&#xD;
&#xD;
          2. Presence of any intracranial mass&#xD;
&#xD;
          3. Traumatic hemorrhagic pleural effusion&#xD;
&#xD;
          4. Major hemorrhage, coincidental stroke, or major trauma&#xD;
&#xD;
          5. High-risk for systemic bleeding&#xD;
&#xD;
          6. Allergy or intolerance to dornase alfa&#xD;
&#xD;
          7. Active clinically serious infection &gt; CTCAE (version 4.03) Grade 2.&#xD;
&#xD;
          8. Serious non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          9. Major surgery, open biopsy or significant traumatic injury within seven (7) days of&#xD;
             first study drug--including neurosurgery.&#xD;
&#xD;
         10. Inability to complete informed consent process and adhere to the protocol treatment&#xD;
             plan and follow-up requirements.&#xD;
&#xD;
         11. Concurrent severe illness such as active infection, or psychiatric illness/social&#xD;
             situations that would limit safety and compliance with study requirements.&#xD;
&#xD;
         12. Patients who are pregnant or lactating (females of childbearing potential must have a&#xD;
             negative pregnancy test prior to participation in this study)&#xD;
&#xD;
         13. Expected survival less than six weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven B Standiford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Regional Medical Center, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven B Standiford, MD</last_name>
    <phone>215-537-7400</phone>
    <email>steven.standiford@ctca-hope.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven B Standiford, MD</last_name>
      <phone>215-537-7400</phone>
      <email>steven.standiford@ctca-hope.com</email>
    </contact>
    <contact_backup>
      <last_name>Jack Medendorp</last_name>
      <phone>215-537-3160</phone>
      <email>jack.medendorp@ctca-hope.com</email>
    </contact_backup>
    <investigator>
      <last_name>Steven B Standiford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emil Abramian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey B Hoag, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 8, 2014</study_first_submitted>
  <study_first_submitted_qc>May 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2014</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

